The domestic corporation Quantamatrix's early Alzheimer’s disease diagnostic aid test, "Altsplus," is set to make a full entry into the domestic non-reimbursed market.
Quantamatrix noted on the 16th that "Altsplus" can be billed as a non-reimbursed medical service at healthcare facilities starting from the 23rd due to the completion of the Ministry of Health and Welfare notification. This is based on the partial amendment to the "evaluation deferment new medical technology notification" announced on the 13th. This notification allows domestic medical institutions and health examination centers to introduce Altsplus.
According to the company, Altsplus is a testing method that simultaneously checks four biomarkers affecting the inhibition, aggregation, and accumulation of amyloid beta (Aβ), which causes Alzheimer’s disease. It obtained item approval from the Ministry of Food and Drug Safety in 2020. By adopting automated testing equipment, it minimized the impact of the tester's skill level. The artificial intelligence (AI) algorithm analyzes the test results to enhance the accuracy of predicting the progression and risk of Alzheimer’s disease.
The company stated, "Unlike other tests, even though it is a blood test, it has a high correlation with cognitive ability tests and is being evaluated as a product that can be the cornerstone of a new market called 'brain health.' We expect to soon finalize the first contract as there is interest from various domestic distributors and testing institutions regarding the product."